Malignant News and Research

RSS

Biovest seeks Health Canada approval of BiovaxID for follicular NHL

Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today announced that Biovest is seeking marketing approval in Canada for BiovaxID, its personalized cancer vaccine for the treatment of follicular non-Hodgkin's lymphoma, an incurable cancer of the immune system.

10 Apr 2012

Fatty acids fight cancer spread

Tiny agents found in omega-3 could potentially be used to block the path of primary cancer tumors, preventing the advance to secondary stage cancers according to pharmacy researchers at the University of Sydney.

9 Apr 2012

Bimodal genes can define molecular subtypes of ovarian cancer

Scientists from Duke University Medical Center have determined that genes acting as molecular "on/off" switches can define clinically relevant molecular subtypes of ovarian cancer, providing ideal potential targets for use in clinical prognostic and diagnostic testing.

9 Apr 2012

More than 4 in 10 people at high risk for hereditary pancreatic cancer have small lesions

A team of scientists led by Johns Hopkins researchers have found that more than four in 10 people considered at high risk for hereditary pancreatic cancer have small pancreatic lesions long before they have any symptoms of the deadly disease.

5 Apr 2012

Exposure to arsenic can turn normal stem cells into cancer stem cells

Researchers at the National Institutes of Health have discovered how exposure to arsenic can turn normal stem cells into cancer stem cells and spur tumor growth. Inorganic arsenic, which affects the drinking water of millions of people worldwide, has been previously shown to be a human carcinogen.

4 Apr 2012

Reactivation of p53 may be a highly selective treatment modality for virally-induced lymphoma

Kaposi's sarcoma herpesvirus (KSHV) is a human tumor virus and an etiological agent for Kaposi's sarcoma and primary effusion lymphoma (PEL). PELs are aggressive lymphomas with reported median survival time shorter than six months after diagnosis.

4 Apr 2012

Safe method for destroying cancer cells using death cap mushroom poison

The mere thought of an identification error sends a chill down the spine of any mushroom lover: The death cap mushroom (Amanita phalloides), which resembles the common white button mushroom, contains one of the most deadly poisons found in nature, α-amanitin.

2 Apr 2012

Combination of Avastin and Metformin may effectively reduce melanoma growth

COMBINING the experimental drug Avastin (bevacizumab) with the diabetes drug Metformin almost doubles its ability to reduce skin cancer growth, according to a study in Cancer Discovery.

2 Apr 2012

Three leading cancer researchers to chair symposia at ACCR meeting

Three leading cancer researchers at Albert Einstein College of Medicine of Yeshiva University have been selected to chair symposia at this year's annual meeting of the American Association for Cancer Research, which will be held in Chicago from March 31 to April 4.

31 Mar 2012

Study identifies key mechanism behind breast cancer metastasis

A new study has identified a key mechanism that causes breast cancer to spread. The research, published by Cell Press on March 30th in the journal Molecular Cell, enhances our knowledge about the signals that drive cancer metastasis and identifies new therapeutic targets for a lethal form of invasive breast cancer that is notoriously resistant to treatment.

30 Mar 2012

Latest updates in clinical practice decision-making in cancer care presented at NCCN 17th conference

The National Comprehensive Cancer Network (NCCN) held the NCCN 17th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care, March 14 - 18 at The Westin Diplomat in Hollywood, Florida. The latest updates in clinical practice decision-making in cancer care were presented, including, but not limited to, the new NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Lung Cancer Screening and updates to the NCCN Guidelines for Melanoma and Non-Hodgkin's Lymphomas.

29 Mar 2012

Change in registry protocols leads to underreporting of myeloid malignancies

Researchers at Moffitt Cancer Center in Tampa, Fla., and colleagues from the UF Shands Cancer Center in Gainesville, Fla., have found that cases of myeloid malignancies are being underreported since a change in registry protocols and laboratory practices starting in 2001.

29 Mar 2012

Increasing incidences of brain tumours calls for more spend on vital research

With more children and people under the age of 40 dying of a brain tumour than any other cancer in the United Kingdom, a leading researcher at Queen's University Belfast is calling for an increase in spending on vital research.

29 Mar 2012

Nature journal publishes first volume of Cancer Cell Line Encyclopedia

The goal of cancer treatment is to match the right drug to the right target in the right patient. But before such "personalized" drugs can be developed, more knowledge is needed about specific genomic alterations in cancers and their sensitivity to potential therapeutic agents.

29 Mar 2012

Invasive strategy benefits patients with myotonic dystrophy type 1 neuromuscular disorder

Patients with a cardiac irregularity and myotonic dystrophy type 1 (a severe neuromuscular disorder with a high risk of sudden death) who received an invasive treatment strategy that included testing of their heart's electrical conduction system and if needed, implantation of a device such as a pacemaker, had an associated higher rate of 9-year survival compared to patients treated noninvasively, according to a study in the March 28 issue of JAMA.

28 Mar 2012

Improper preparation for colonoscopy hides pre-cancerous polyps

What happens on the day before a colonoscopy may be just as important as the colon-screening test itself.

28 Mar 2012

Imatinib improves RFS, overall survival in GIST patients after surgery

Among patients with a high risk of recurrence of a gastrointestinal stromal tumor following surgery for its removal, patients who received imatinib (a drug to treat certain cancers) for 3 years instead of 1 had improved recurrence-free survival and overall survival, according to a study in the March 28 issue of JAMA.

28 Mar 2012